scholarly article | Q13442814 |
P50 | author | Robert J. Linhardt | Q7345927 |
Shaun K Olsen | Q54253067 | ||
Regina Goetz | Q57078008 | ||
Makoto Kuro-o | Q88749584 | ||
Anna V Eliseenkova | Q114419632 | ||
Hiroshi Kurosu | Q123475544 | ||
Moosa Mohammadi | Q37382162 | ||
Xijie Yu | Q38545234 | ||
P2093 | author name string | Thomas A Neubert | |
Omar A Ibrahimi | |||
Yasushi Ogawa | |||
Beate Lanske | |||
Juliya Kalinina | |||
Steven A Kliewer | |||
Fuming Zhang | |||
Mohammed S Razzaque | |||
Takeshi Inagaki | |||
Kenneth E White | |||
Masaya Yamamoto | |||
Andrew Beenken | |||
ChongFeng Xu | |||
P2860 | cites work | Crystal structures of two FGF-FGFR complexes reveal the determinants of ligand-receptor specificity | Q22254157 |
Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization | Q24290400 | ||
Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23 | Q24290481 | ||
Structural basis by which alternative splicing confers specificity in fibroblast growth factor receptors | Q24294933 | ||
Kinetic model for FGF, FGFR, and proteoglycan signal transduction complex assembly | Q44850723 | ||
A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis | Q46609225 | ||
Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. | Q51485180 | ||
Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. | Q53964449 | ||
Structural basis by which alternative splicing modulates the organizer activity of FGF8 in the brain | Q24300036 | ||
Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis | Q24305561 | ||
Mutation of the mouse klotho gene leads to a syndrome resembling ageing | Q24328782 | ||
FGF-21 as a novel metabolic regulator | Q24523933 | ||
Fibroblast growth factors | Q24542507 | ||
Identification of receptor and heparin binding sites in fibroblast growth factor 4 by structure-based mutagenesis | Q24550863 | ||
Crystal structure of fibroblast growth factor 9 reveals regions implicated in dimerization and autoinhibition | Q27627811 | ||
Structural basis for interaction of FGF-1, FGF-2, and FGF-7 with different heparan sulfate motifs | Q27636426 | ||
The crystal structure of fibroblast growth factor (FGF) 19 reveals novel features of the FGF family and offers a structural basis for its unusual receptor affinity | Q27642980 | ||
Structural studies of the binding of the anti-ulcer drug sucrose octasulfate to acidic fibroblast growth factor | Q27729397 | ||
Stereochemical quality of protein structure coordinates | Q27860874 | ||
Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23 | Q28209679 | ||
Three-Dimensional Structures of Acidic and Basic Fibroblast Growth Factors | Q28267322 | ||
Klotho converts canonical FGF receptor into a specific receptor for FGF23 | Q28272505 | ||
beta-Trefoil fold. Patterns of structure and sequence in the Kunitz inhibitors interleukins-1 beta and 1 alpha and fibroblast growth factors | Q28294610 | ||
Fibroblast growth factor signaling during early vertebrate development | Q28305654 | ||
Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice | Q28507303 | ||
The glycine box: a determinant of specificity for fibroblast growth factor | Q28574386 | ||
Regulation of fibroblast growth factor-23 signaling by klotho | Q28587100 | ||
Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis | Q29619610 | ||
Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism | Q29620323 | ||
Impaired negative feedback suppression of bile acid synthesis in mice lacking betaKlotho | Q33905745 | ||
Biochemical analysis of pathogenic ligand-dependent FGFR2 mutations suggests distinct pathophysiological mechanisms for craniofacial and limb abnormalities | Q34074836 | ||
Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity | Q34123954 | ||
Structural basis for fibroblast growth factor receptor activation | Q36111391 | ||
A protein canyon in the FGF-FGF receptor dimer selects from an à la carte menu of heparan sulfate motifs | Q36254487 | ||
Functions and regulations of fibroblast growth factor signaling during embryonic development | Q36282338 | ||
Mutations uncouple human fibroblast growth factor (FGF)-7 biological activity and receptor binding and support broad specificity in the secondary receptor binding site of FGFs. | Q40915825 | ||
Premature aging-like phenotype in fibroblast growth factor 23 null mice is a vitamin D-mediated process | Q42736434 | ||
Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia | Q44203982 | ||
Klotho is a novel beta-glucuronidase capable of hydrolyzing steroid beta-glucuronides | Q44710659 | ||
P433 | issue | 9 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | cell biology | Q7141 |
P304 | page(s) | 3417-28 | |
P577 | publication date | 2007-05-01 | |
P1433 | published in | Molecular and Cellular Biology | Q3319478 |
P1476 | title | Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members | |
P478 | volume | 27 |
Q93105582 | A G protein-coupled, IP3/protein kinase C pathway controlling the synthesis of phosphaturic hormone FGF23 |
Q28478454 | A better anti-diabetic recombinant human fibroblast growth factor 21 (rhFGF21) modified with polyethylene glycol |
Q51308109 | A computationally identified compound antagonizes excess FGF-23 signaling in renal tubules and a mouse model of hypophosphatemia. |
Q48506046 | A novel approach to improve the function of FGF21. |
Q27687316 | A potential link between phosphate and aging--lessons from Klotho-deficient mice |
Q36942098 | A role for fibroblast growth factor 19 and bile acids in diabetes remission after Roux-en-Y gastric bypass |
Q90428920 | A systematic dissection of sequence elements determining β-Klotho and FGF interaction and signaling |
Q38351110 | Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models--association with liver and adipose tissue effects |
Q51709073 | Antibody to fibroblast growth factor 23-peptide reduces excreta phosphorus of laying hens. |
Q89260331 | Association of serum intact fibroblast growth factor 23 with left ventricular mass and different echocardiographic findings in patients on hemodialysis |
Q50297643 | Autocatalytic phosphorylation of BetaKlotho-bound FGFR4 |
Q26800206 | Bile Acid Metabolism and Signaling in Cholestasis, Inflammation, and Cancer |
Q37404983 | Biochemical and functional characterization of the klotho-VS polymorphism implicated in aging and disease risk |
Q47989110 | Biology of Fibroblast Growth Factor 23: From Physiology to Pathology |
Q39666379 | Both FGF23 and extracellular phosphate activate Raf/MEK/ERK pathway via FGF receptors in HEK293 cells |
Q39581682 | Brown adipose tissue responds to cold and adrenergic stimulation by induction of FGF21. |
Q90469042 | C-FGF23 peptide alleviates hypoferremia during acute inflammation |
Q24317949 | C-terminal tail of FGF19 determines its specificity toward Klotho co-receptors |
Q36966608 | Can fibroblast growth factor 23 fine-tune therapies for diseases of abnormal mineral ion metabolism? |
Q36023924 | Canine Fibroblast Growth Factor 21 Ameliorates Hyperglycemia Associated with Inhibiting Hepatic Gluconeogenesis and Improving Pancreatic Beta-Cell Survival in Diabetic Mice and Dogs |
Q38977291 | Cardiac actions of fibroblast growth factor 23. |
Q47916949 | Cardiomyokines from the heart |
Q28730955 | Characterization of a FGF19 variant with altered receptor specificity revealed a central role for FGFR1c in the regulation of glucose metabolism |
Q40478618 | Chronic Hyperphosphatemia and Vascular Calcification Are Reduced by Stable Delivery of Soluble Klotho. |
Q55052281 | Chronic diarrhea caused by idiopathic bile acid malabsorption: an explanation at last. |
Q24603434 | Chronic diarrhea due to excessive bile acid synthesis and not defective ileal transport: a new syndrome of defective fibroblast growth factor 19 release |
Q21135215 | Circulating fibroblast growth factor 21 levels are closely associated with hepatic fat content: a cross-sectional study |
Q41760918 | Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. |
Q34989319 | Clinical Significance of FGF-23 in Patients with CKD. |
Q37641052 | Clinical relevance of FGF-23 in chronic kidney disease |
Q34665759 | Co-receptor requirements for fibroblast growth factor-19 signaling |
Q36801775 | Combined sequence and sequence-structure based methods for analyzing FGF23, CYP24A1 and VDR genes |
Q38757058 | Convergent Signaling Pathways Regulate Parathyroid Hormone and Fibroblast Growth Factor-23 Action on NPT2A-mediated Phosphate Transport |
Q36217292 | Conversion of a paracrine fibroblast growth factor into an endocrine fibroblast growth factor |
Q37417445 | Defective O-glycosylation due to a novel homozygous S129P mutation is associated with lack of fibroblast growth factor 23 secretion and tumoral calcinosis |
Q24312210 | Different roles of N- and C- termini in the functional activity of FGF21 |
Q33910462 | Differential interactions of FGFs with heparan sulfate control gradient formation and branching morphogenesis |
Q39374896 | Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB. |
Q51379603 | Direct effects of FGF21 on glucose uptake in human skeletal muscle: implications for type 2 diabetes and obesity. |
Q104073661 | Discovery of a novel fibroblast activation protein (FAP) inhibitor, BR103354, with anti-diabetic and anti-steatotic effects |
Q36407996 | Diversification of the structural determinants of fibroblast growth factor-heparin interactions: implications for binding specificity |
Q43078080 | Does FGF23 toxicity influence the outcome of chronic kidney disease? |
Q37182735 | Does Fgf23-klotho activity influence vascular and soft tissue calcification through regulating mineral ion metabolism? |
Q36016804 | Dynamics and Distribution of Klothoβ (KLB) and fibroblast growth factor receptor-1 (FGFR1) in living cells reveal the fibroblast growth factor-21 (FGF21)-induced receptor complex |
Q28085476 | Dysregulation of phosphate metabolism and conditions associated with phosphate toxicity |
Q53699390 | Effect of Salt Intervention on Serum Levels of Fibroblast Growth Factor 23 (FGF23) in Chinese Adults: An Intervention Study. |
Q34064416 | Effects of short-term continuous subcutaneous insulin infusion on fasting plasma fibroblast growth factor-21 levels in patients with newly diagnosed type 2 diabetes mellitus |
Q50692928 | Elevated fibroblast growth factor 23 exerts its effects on placenta and regulates vitamin D metabolism in pregnancy of Hyp mice. |
Q24629260 | Endocrine fibroblast growth factors 15/19 and 21: from feast to famine |
Q36982323 | Endocrine functions of bone in mineral metabolism regulation. |
Q33927113 | Enhanced in vitro refolding of fibroblast growth factor 15 with the assistance of SUMO fusion partner |
Q47750111 | Ensemble docking to difficult targets in early-stage drug discovery: Methodology and application to fibroblast growth factor 23. |
Q35073296 | Evaluation of hypophosphatemia: lessons from patients with genetic disorders. |
Q27015054 | Exploring mechanisms of FGF signalling through the lens of structural biology |
Q45787218 | Expression of FGF19 in human embryonic stem cells. |
Q54227364 | Expression of Fibroblast Growth Factor 21 and β-Klotho Regulates Hepatic Fibrosis through the Nuclear Factor-κB and c-Jun N-Terminal Kinase Pathways. |
Q38031216 | FGF-23: the rise of a novel cardiovascular risk marker in CKD. |
Q98906651 | FGF/FGFR signaling in health and disease |
Q35549802 | FGF1 and FGF19 reverse diabetes by suppression of the hypothalamic-pituitary-adrenal axis |
Q42789527 | FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1α pathway |
Q42027804 | FGF15/FGFR4 integrates growth factor signaling with hepatic bile acid metabolism and insulin action |
Q46735156 | FGF19 (fibroblast growth factor 19) as a novel target gene for activating transcription factor 4 in response to endoplasmic reticulum stress |
Q93216608 | FGF21 Mimics a Fasting-Induced Metabolic State and Increases Appetite in Zebrafish |
Q24322074 | FGF21 N- and C-termini play different roles in receptor interaction and activation |
Q40667176 | FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents |
Q42176870 | FGF21 as an Endocrine Regulator in Lipid Metabolism: From Molecular Evolution to Physiology and Pathophysiology |
Q30414627 | FGF21 contributes to neuroendocrine control of female reproduction |
Q24653481 | FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response |
Q54960612 | FGF23 Actions on Target Tissues-With and Without Klotho. |
Q90624325 | FGF23 and Associated Disorders of Phosphate Wasting |
Q37996937 | FGF23 and PTH--double agents at the heart of CKD. |
Q34017992 | FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. |
Q34028891 | FGF23 induces left ventricular hypertrophy |
Q28509196 | FGF23 promotes renal calcium reabsorption through the TRPV5 channel |
Q43074642 | FGF23-induced hypophosphatemia persists in Hyp mice deficient in the WNT coreceptor Lrp6. |
Q24653541 | FGF23-mediated regulation of systemic phosphate homeostasis: is Klotho an essential player? |
Q37654689 | FGF23-parathyroid interaction: implications in chronic kidney disease |
Q55409905 | FGF23C-tail improves diabetic nephropathy by attenuating renal fibrosis and inflammation. |
Q102379407 | FGF401 and vinorelbine synergistically mediate antitumor activity and vascular normalization in FGF19-dependent hepatocellular carcinoma |
Q99605475 | FGFR Fusions in Cancer: From Diagnostic Approaches to Therapeutic Intervention |
Q50297642 | FGFR4 binds HS:KLB:FGF19 |
Q38794405 | Fibroblast Growth Factor 21 As an Emerging Therapeutic Target for Type 2 Diabetes Mellitus |
Q26766528 | Fibroblast Growth Factor 21 Protects against Atherosclerosis via Fine-Tuning the Multiorgan Crosstalk |
Q90224598 | Fibroblast Growth Factor 21 and the Adaptive Response to Nutritional Challenges |
Q88238584 | Fibroblast Growth Factor 23 is Associated With Adiposity in Patients Receiving Hemodialysis: Possible Cross Talk Between Bone and Adipose Tissue |
Q26772751 | Fibroblast Growth Factor Signaling in Metabolic Regulation |
Q92599809 | Fibroblast growth factor 21 ameliorates pancreatic fibrogenesis via regulating polarization of macrophages |
Q64889156 | Fibroblast growth factor 21 in chronic kidney disease. |
Q35266374 | Fibroblast growth factor 21 induces glucose transporter-1 expression through activation of the serum response factor/Ets-like protein-1 in adipocytes |
Q34674492 | Fibroblast growth factor 21 is a metabolic regulator that plays a role in the adaptation to ketosis. |
Q35779219 | Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ. |
Q43224118 | Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice |
Q37412337 | Fibroblast growth factor 21: an overview from a clinical perspective |
Q24658126 | Fibroblast growth factor 21: from pharmacology to physiology |
Q30544587 | Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism |
Q24604832 | Fibroblast growth factor 23 inhibits extrarenal synthesis of 1,25-dihydroxyvitamin D in human monocytes |
Q38072361 | Fibroblast growth factor 23: associations with cardiovascular disease and mortality in chronic kidney disease |
Q36413230 | Fibroblast growth factor 23: state of the field and future directions |
Q27011668 | Fibroblast growth factor signaling in the vasculature |
Q98513768 | Fibroblast growth factor signalling in osteoarthritis and cartilage repair |
Q53791866 | Fibroblast growth factor-21 restores insulin sensitivity but induces aberrant bone microstructure in obese insulin-resistant rats. |
Q64973345 | Fibroblast growth factors 19 and 21 in acute liver damage. |
Q36923642 | Fibroblast growth factors, old kids on the new block |
Q35020888 | Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease |
Q28473286 | Genetic evidence of serum phosphate-independent functions of FGF-23 on bone |
Q47149133 | Hepatic Crtc2 controls whole body energy metabolism via a miR-34a-Fgf21 axis |
Q39118846 | Heritable and acquired disorders of phosphate metabolism: Etiologies involving FGF23 and current therapeutics |
Q27646372 | Homodimerization Controls the Fibroblast Growth Factor 9 Subfamily's Receptor Binding and Heparan Sulfate-Dependent Diffusion in the Extracellular Matrix |
Q37781747 | Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease |
Q28550659 | Human FGF-21 Is a Substrate of Fibroblast Activation Protein |
Q38045788 | Hypophosphatemic rickets: unraveling the role of FGF23. |
Q38811612 | IL-1β inhibits β-Klotho expression and FGF19 signaling in hepatocytes |
Q37072412 | In vivo genetic evidence for klotho-dependent, fibroblast growth factor 23 (Fgf23) -mediated regulation of systemic phosphate homeostasis |
Q37415834 | Inactivation of klotho function induces hyperphosphatemia even in presence of high serum fibroblast growth factor 23 levels in a genetically engineered hypophosphatemic (Hyp) mouse model |
Q42857128 | Increased FGF21 plasma levels in humans with sepsis and SIRS. |
Q35222785 | Increased fibroblast growth factor 21 expression in high-fat diet-sensitive non-human primates (Macaca mulatta). |
Q36863458 | Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production |
Q38343318 | Influence of heparin mimetics on assembly of the FGF.FGFR4 signaling complex. |
Q34695191 | Initial FGF23-mediated signaling occurs in the distal convoluted tubule |
Q50592611 | Instability restricts signaling of multiple fibroblast growth factors. |
Q88220668 | Interleukin-1-induced acute bone resorption facilitates the secretion of fibroblast growth factor 23 into the circulation |
Q43040953 | Intestinal FXR-mediated FGF15 production contributes to diurnal control of hepatic bile acid synthesis in mice |
Q49610814 | Is fibroblast growth factor 23 a new cardiovascular risk marker in gestational diabetes? |
Q33591785 | Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation |
Q41889886 | KLB, encoding β-Klotho, is mutated in patients with congenital hypogonadotropic hypogonadism |
Q37591992 | Klotho |
Q41900414 | Klotho and Na+,K+-ATPase activity: solving the calcium metabolism dilemma? |
Q39887303 | Klotho and fibroblast growth factor 23 in cerebrospinal fluid in children. |
Q35033538 | Klotho and the aging process |
Q38016065 | Klotho as a potential biomarker and therapy for acute kidney injury |
Q37051351 | Klotho as a regulator of oxidative stress and senescence |
Q35943927 | Klotho coreceptors inhibit signaling by paracrine fibroblast growth factor 8 subfamily ligands |
Q34624546 | Klotho inhibits transforming growth factor-beta1 (TGF-beta1) signaling and suppresses renal fibrosis and cancer metastasis in mice |
Q55418554 | Klotho negatively regulated aerobic glycolysis in colorectal cancer via ERK/HIF1α axis. |
Q38115124 | Klotho, phosphate and FGF-23 in ageing and disturbed mineral metabolism |
Q90225367 | Klotho: A Major Shareholder in Vascular Aging Enterprises |
Q54358347 | Large-scale expression, purification, and glucose uptake activity of recombinant human FGF21 in Escherichia coli. |
Q33791650 | Left ventricular mass progression despite stable blood pressure and kidney function in stage 3 chronic kidney disease. |
Q24319088 | Liver-specific activities of FGF19 require Klotho beta |
Q38871624 | Long-Term Administration of Fibroblast Growth Factor 21 Prevents Chemically-Induced Hepatocarcinogenesis in Mice |
Q36878769 | Mesenchymal stem cell-derived exosomes facilitate nasopharyngeal carcinoma progression |
Q36746670 | Metabolic fibroblast growth factors (FGFs): Mediators of energy homeostasis |
Q27321257 | Metabolic hormone FGF21 is induced in ground squirrels during hibernation but its overexpression is not sufficient to cause torpor |
Q39676210 | Metabolic regulator betaKlotho interacts with fibroblast growth factor receptor 4 (FGFR4) to induce apoptosis and inhibit tumor cell proliferation |
Q38066238 | Metabolic syndrome in youth: current insights and novel serum biomarkers |
Q36107291 | Minireview: Roles of Fibroblast Growth Factors 19 and 21 in Metabolic Regulation and Chronic Diseases |
Q47974129 | Mitochondrial diseases: the contribution of organelle stress responses to pathology |
Q42959191 | Mitochondrial myopathy induces a starvation-like response |
Q37495906 | Modulation of fibroblast growth factor 19 expression by bile acids, meal replacement and energy drinks, milk, and coffee |
Q55490578 | Molecular elements in FGF19 and FGF21 defining KLB/FGFR activity and specificity. |
Q36956055 | Molecular genetic and biochemical analyses of FGF23 mutations in familial tumoral calcinosis |
Q37448279 | Molecular genetics of parathyroid disease. |
Q28291993 | Molecular mechanisms of fibroblast growth factor signaling in physiology and pathology |
Q37475258 | Molecular pathology of the fibroblast growth factor family |
Q37631288 | Molecular subclasses of hepatocellular carcinoma predict sensitivity to fibroblast growth factor receptor inhibition |
Q33888883 | Multiplexed gene expression profiling identifies the FGFR4 pathway as a novel biomarker in intrahepatic cholangiocarcinoma |
Q92243130 | Nasal Placode Development, GnRH Neuronal Migration and Kallmann Syndrome |
Q89726482 | Novel Abs targeting the N-terminus of fibroblast growth factor 19 inhibit hepatocellular carcinoma growth without bile-acid-related side-effects |
Q27009136 | Novel aspects of brown adipose tissue biology |
Q35227185 | Nrf2 represses FGF21 during long-term high-fat diet-induced obesity in mice |
Q42541748 | Nuclear localization of Klotho in brain: an anti-aging protein |
Q34768206 | Numerous isoforms of Fgf8 reflect its multiple roles in the developing brain |
Q35059741 | Osteo-renal regulation of systemic phosphate metabolism |
Q37559361 | Overview of the FGF23-Klotho axis |
Q41137474 | PAI-1 is a critical regulator of FGF23 homeostasis |
Q55221465 | Paracrine Effects of FGF23 on the Heart. |
Q92535838 | Paracrine Fibroblast Growth Factor 1 Functions as Potent Therapeutic Agent for Intrahepatic Cholestasis by Downregulating Synthesis of Bile Acid |
Q35069203 | Parathyroid-specific deletion of Klotho unravels a novel calcineurin-dependent FGF23 signaling pathway that regulates PTH secretion |
Q35581474 | Pharmacokinetics (PK), pharmacodynamics (PD) and integrated PK/PD modeling of a novel long acting FGF21 clinical candidate PF-05231023 in diet-induced obese and leptin-deficient obese mice |
Q92763064 | Pharmacologic Modulation of Bile Acid-FXR-FGF15/FGF19 Pathway for the Treatment of Nonalcoholic Steatohepatitis |
Q35059905 | Phosphate toxicity: new insights into an old problem |
Q55375521 | Physiological Actions of Fibroblast Growth Factor-23. |
Q27675418 | Plasticity in Interactions of Fibroblast Growth Factor 1 (FGF1) N Terminus with FGF Receptors Underlies Promiscuity of FGF1 |
Q54139850 | Pleiotropic Actions of FGF23. |
Q47151186 | Prokaryotic soluble expression and purification of bioactive human fibroblast growth factor 21 using maltose-binding protein. |
Q30365689 | Prox1 and fibroblast growth factor receptors form a novel regulatory loop controlling lens fiber differentiation and gene expression |
Q28485340 | Rationale-Based Engineering of a Potent Long-Acting FGF21 Analog for the Treatment of Type 2 Diabetes |
Q26860470 | Regulation and function of the FGF23/klotho endocrine pathways |
Q38652926 | Regulation of Receptor Binding Specificity of FGF9 by an Autoinhibitory Homodimerization |
Q28070054 | Regulation of fibroblast growth factor 15/19 and 21 on metabolism: in the fed or fasted state |
Q28506271 | Regulation of serum 1,25(OH)2 vitamin D3 levels by fibroblast growth factor 23 is mediated by FGF receptors 3 and 4 |
Q26781431 | Research Perspectives on the Regulation and Physiological Functions of FGF21 and its Association with NAFLD |
Q34197301 | Research resource: Comprehensive expression atlas of the fibroblast growth factor system in adult mouse. |
Q35755137 | Role of FGF/FGFR signaling in skeletal development and homeostasis: learning from mouse models |
Q41974026 | Role of FGF19 induced FGFR4 activation in the regulation of glucose homeostasis |
Q39411310 | SUMO fusion system facilitates soluble expression and high production of bioactive human fibroblast growth factor 23 (FGF23). |
Q37303131 | Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice |
Q34069794 | Separating mitogenic and metabolic activities of fibroblast growth factor 19 (FGF19). |
Q89489779 | Serum Endocrine Fibroblast Growth Factors as Potential Biomarkers for Chronic Kidney Disease and Various Metabolic Dysfunctions in Aged Patients |
Q92439873 | Skeletal mineralization: mechanisms and diseases |
Q41844942 | Soluble expression of disulfide bond containing proteins FGF15 and FGF19 in the cytoplasm of Escherichia coli |
Q39259520 | Sulfated glycosaminoglycan-assisted receptor specificity of human fibroblast growth factor (FGF) 19 signaling in a mouse system is different from that in a human system |
Q24306135 | Sulfated glycosaminoglycans are required for specific and sensitive fibroblast growth factor (FGF) 19 signaling via FGF receptor 4 and betaKlotho |
Q42343453 | Targeting FGF19/FGFR4 Pathway: A Novel Therapeutic Strategy for Hepatocellular Carcinoma. |
Q37231731 | Targeting bile-acid signalling for metabolic diseases |
Q42545128 | Temporal and spatial expression of FGF ligands and receptors during Xenopus development |
Q64118923 | The EPO-FGF23 Signaling Pathway in Erythroid Progenitor Cells: Opening a New Area of Research |
Q36933339 | The FGF family: biology, pathophysiology and therapy |
Q34467171 | The Fibroblast Growth Factor signaling pathway |
Q93222971 | The Klotho proteins in health and disease |
Q92049636 | The Level of FGF 21 as a New Risk Factor for the Occurrence of Cardiometabolic Disorders amongst the Psoriatic Patients |
Q38571195 | The PTH-Vitamin D-FGF23 axis |
Q30234616 | The Role and Potential Therapeutic Implications of the Fibroblast Growth Factors in Energy Balance and Type 2 Diabetes |
Q92959917 | The Role of Fibroblast Growth Factor 23 in Inflammation and Anemia |
Q24602026 | The alternatively spliced acid box region plays a key role in FGF receptor autoinhibition |
Q36860289 | The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis |
Q28572613 | The parathyroid is a target organ for FGF23 in rats |
Q55513236 | The role of FGF21 in type 1 diabetes and its complications. |
Q36992839 | The role of Klotho in energy metabolism |
Q38235454 | The role of fibroblast growth factor 21 in the pathogenesis of liver disease: a novel predictor and therapeutic target |
Q36928572 | The structural biology of the FGF19 subfamily |
Q38732752 | Therapeutic Effects of FGF23 c-tail Fc in a Murine Preclinical Model of X-Linked Hypophosphatemia Via the Selective Modulation of Phosphate Reabsorption |
Q37767247 | Therapeutic management of post-kidney transplant hyperparathyroidism |
Q42529430 | Therapeutic potential of klotho-FGF23 fusion polypeptides: WO2009095372 |
Q38633258 | Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. |
Q30407643 | Therapeutic utilities of fibroblast growth factor 19. |
Q34778879 | Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21. |
Q24318639 | Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21 |
Q47795793 | Uncoupling the Mitogenic and Metabolic Functions of FGF1 by Tuning FGF1-FGF Receptor Dimer Stability |
Q39411644 | Understanding the physical interactions in the FGF21/FGFR/β-Klotho complex: structural requirements and implications in FGF21 signaling |
Q33888727 | Vitamin D: metabolism |
Q42133772 | What can FGF23 do without Klotho? |
Q36977082 | beta-Klotho and FGF-15/19 inhibit the apical sodium-dependent bile acid transporter in enterocytes and cholangiocytes |
Q50001744 | α-Klotho is a non-enzymatic molecular scaffold for FGF23 hormone signalling |
Search more.